Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

被引：4
|
作者：
Marin, Ellen [1 ]
Scott, Sara [2 ]
Maples, Kathryn [3 ]
Joseph, Nisha S. [4 ]
Hofmeister, Craig C. [5 ]
Gupta, Vikas A. [5 ]
Dhodapkar, Madhav V. [5 ]
Kaufman, Jonathan L. [5 ]
Lonial, Sagar [6 ]
Nooka, Ajay K. [2 ]
机构：
[1] Emory Univ Hosp, Winship Canc Inst, Decatur, GA USA
[2] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Pfizer, Atlanta, GA USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] ANV-419Cytokine release syndrome (CRS) in the form of hypotension, fever, chills and CRS: 2 case reports
    Reactions Weekly, 2024, 2028 (1) : 65 - 65
  • [32] Teclistamab/thalidomideCytokine release syndrome and lack of efficacy
    Reactions Weekly, 2024, 2009 (1) : 545 - 545
  • [33] ALLEVIATION OF OKT3-INDUCED CYTOKINE RELEASE SYNDROME (CRS) WITH PENTOXIFYLLINE (PTX)
    HOLDAAS, H
    WAAGE, A
    BENTDAL, O
    SUNDAL, E
    HARTMANN, A
    NORDAL, K
    FAUCHALD, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 1011 - 1011
  • [34] CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY IN CAR-T CELL THERAPY PATIENTS
    Delrosario, Maria Regina
    Davison, Lisa
    Schwen, Sarah
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [35] TOCILIZUMAB FOR CYTOKINE RELEASE SYNDROME IN SEVERE COVID-19 PNEUMONIA: A CASE SERIES
    Boparai, Sukhmani
    Siddiqui, Najam
    Hansra, Rajkamal
    Scott, L.
    Motayar, Nasim
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 83 - 83
  • [36] Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome
    Minami, Soichiro
    Kawashima, Yosuke
    Munakata, Yasuhiko
    Matsuno, Masahiro
    Hara, Shuichiro
    Yamazaki, Yusuke
    Doman, Tsuyoshi
    Saito, Shin
    Odaka, Tetsuo
    Ogasawara, Takahiro
    Shimizu, Hisashi
    Sugisaka, Jun
    Aiba, Tomoiki
    Toi, Yukihiro
    Yamanda, Shinsuke
    Kimura, Yuichiro
    Sugawara, Shunichi
    CANCER REPORTS, 2024, 7 (07)
  • [37] Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
    Daoudlarian, D.
    Segot, A.
    Latifyan, S.
    Bartolini, R.
    Joo, V.
    Mederos, N.
    Bouchaab, H.
    Demicheli, R.
    Abdelhamid, K.
    Ferahta, N.
    Doms, J.
    Stalder, G.
    Noto, A.
    Mencarelli, L.
    Mosimann, V.
    Berthold, D.
    Stravodimou, A.
    Sartori, C.
    Shabafrouz, K.
    Thompson, J. A.
    Wang, Y.
    Peters, S.
    Pantaleo, G.
    Obeid, M.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 444 - 459
  • [38] Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies
    Perl, Markus
    Herfeld, Konstantin
    Harrer, Dennis C.
    Hoepting, Matthias
    Schweiger, Marina
    Sterz, Ulrich
    Knoedler, Leonard
    Heimerl, Susanne
    Hansmann, Leo
    Herr, Wolfgang
    Poeck, Hendrik
    Wolff, Daniel
    Edinger, Matthias
    Hart, Christina
    Fante, Matthias A.
    HAEMATOLOGICA, 2024, 109 (09) : 2969 - 2977
  • [39] Risk of Cytokine Release Syndrome (CRS) with glofitamab is predicted by an updated model with a potential clinical application
    Subkleve, M.
    Komanduri, K. V.
    Belousov, A.
    Dixon, M.
    Relf, J.
    Tandon, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 207 - 208
  • [40] Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm
    Gonzalez-Rubio, Jesus
    Navarro-Lopez, Carmen
    Lopez-Najera, Elena
    Lopez-Najera, Ana
    Jimenez-Diaz, Lydia
    Navarro-Lopez, Juan D.
    Najera, Alberto
    FRONTIERS IN IMMUNOLOGY, 2020, 11
12345